Syncona Focuses On Creating Commercially Ambitious Businesses
Executive Summary
With £1bn under management, patient capital company Syncona Limited reveals its strategy for creating and building companies that will generate reimbursable products for patients.
You may also be interested in...
Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Syncona CEO On Why Its 10th Start-Up Focuses On T-Regulatory Cell Therapies
UK investment group Syncona Ltd has financed its tenth start-up, Quell Therapeutics, with the aim of developing engineered T regulatory (Treg) cell therapies.
Pharmaleads CEO Outlines Pipeline Of Non-Opiate Pain Therapies
On the sidelines of the 2017 BIO-Europe partnering meeting, Scrip talks to Thierry Bourbié, chair and CEO of Pharmaleads, a pharmaceutical company developing non-opiate products for the management of acute and chronic severe pain.